Turnstone Biologics Corp. Common Stock Total Liabilities
Turnstone Biologics Corp. Common Stock total liabilities. Based on the latest financial reports, Turnstone Biologics Corp. Common Stock (TSBX) has total liabilities worth $6.34 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TSBX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Turnstone Biologics Corp. Common Stock (2021–2024)
Total liabilities of Turnstone Biologics Corp. Common Stock from 2021 to 2024. This chart illustrates how Turnstone Biologics Corp. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Turnstone Biologics Corp. Common Stock Competitors by Total Liabilities
The table below lists competitors of Turnstone Biologics Corp. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Barramundi Group Ltd
OL:BARRA
|
Norway | Nkr24.80 Million |
|
Cinevista Limited
NSE:CINEVISTA
|
India | Rs818.69 Million |
|
Orcay Ortakoy Cay Sanayi & Ticaret AS
IS:ORCAY
|
Turkey | TL419.20 Million |
|
Pagegroup PLC
LSE:PAGE
|
UK | GBX361.10 Million |
|
Baillie Gifford Japan Trust
LSE:BGFD
|
UK | GBX114.78 Million |
|
EXCELLENCE S.A. ZY -10
F:8XY
|
Germany | €12.95 Million |
|
Walker River Resources Corp.
V:WRR
|
Canada | CA$562.04K |
|
Northann Corp.
NYSE MKT:NCL
|
USA | $11.43 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Turnstone Biologics Corp. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Turnstone Biologics Corp. Common Stock total assets.
Liquidity & Leverage Metrics
Turnstone Biologics Corp. Common Stock Total Liabilities Ratios Explained
Turnstone Biologics Corp. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Turnstone Biologics Corp. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Turnstone Biologics Corp. Common Stock (2021–2024)
The table below shows the annual total liabilities of Turnstone Biologics Corp. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.67 Million | -38.71% |
| 2023-12-31 | $14.15 Million | -93.46% |
| 2022-12-31 | $216.41 Million | -19.58% |
| 2021-12-31 | $269.10 Million | -- |
About Turnstone Biologics Corp. Common Stock
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California. As of August 11, 2025, Turnstone Biologics Corp. operates as a subsidiary of XOMA Royalty Corporation.